AVALO THERAPEUTICS, INC. Current Income Tax Expense (Benefit)
AVALO THERAPEUTICS, INC. (AVTX) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2025 was $0.00.
- AVALO THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2024 was $0.00.
- AVALO THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2023 was $0.00.
- AVALO THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Income Tax Expense (Benefit) 1 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | ||
| 2021-12-31 | -$218.00K 10-K · filed 2023-03-29 | ||
| 2021-03-31 | -$2.60M 10-K · filed 2022-03-02 | ||
| 2020-12-31 | -$2.60M 10-K · filed 2022-03-02 | -$2.60M 10-K · filed 2021-03-08 | |
| 2020-03-31 | -$2.60M 10-K · filed 2023-03-29 | ||
| 2019-12-31 | $263.57K 10-K · filed 2021-03-08 | ||
| 2018-12-31 | -$32.72K 10-K · filed 2020-03-11 | -$17.16K 10-K · filed 2019-03-18 | |
| 2017-12-31 | $2.80M 10-K · filed 2019-03-18 | ||
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |